ES2663096T3 - Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas - Google Patents

Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas Download PDF

Info

Publication number
ES2663096T3
ES2663096T3 ES11790534T ES11790534T ES2663096T3 ES 2663096 T3 ES2663096 T3 ES 2663096T3 ES 11790534 T ES11790534 T ES 11790534T ES 11790534 T ES11790534 T ES 11790534T ES 2663096 T3 ES2663096 T3 ES 2663096T3
Authority
ES
Spain
Prior art keywords
treatment
methods
nephrotic syndrome
related conditions
nephrotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11790534T
Other languages
English (en)
Spanish (es)
Inventor
Sumant S. CHUGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2663096T3 publication Critical patent/ES2663096T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES11790534T 2010-06-05 2011-06-06 Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas Active ES2663096T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35186610P 2010-06-05 2010-06-05
PCT/US2011/039255 WO2011153525A2 (en) 2010-06-05 2011-06-06 Methods for treatment of nephrotic syndrome and related conditions

Publications (1)

Publication Number Publication Date
ES2663096T3 true ES2663096T3 (es) 2018-04-11

Family

ID=45067339

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11790534T Active ES2663096T3 (es) 2010-06-05 2011-06-06 Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas

Country Status (12)

Country Link
EP (2) EP2575858B1 (enExample)
JP (1) JP5904560B2 (enExample)
KR (1) KR20130132375A (enExample)
CN (2) CN103140234B (enExample)
AU (1) AU2011261196B2 (enExample)
CA (1) CA2801579C (enExample)
DK (1) DK2575858T3 (enExample)
ES (1) ES2663096T3 (enExample)
NO (1) NO2575858T3 (enExample)
PL (1) PL2575858T3 (enExample)
PT (1) PT2575858T (enExample)
WO (1) WO2011153525A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110301103A1 (en) 2010-06-05 2011-12-08 Chugh Sumant S Methods of Treatment
US9139629B2 (en) 2010-06-05 2015-09-22 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
JP2016516726A (ja) * 2013-03-15 2016-06-09 ザ・ユー・エイ・ビー・リサーチ・フアンデーシヨン ネフローゼ症候群及び関連状態の治療方法
WO2015107501A1 (en) * 2014-01-20 2015-07-23 Ghiggeri Gian Marco In vitro method for predicting, diagnosing and monitoring in therapeutic follow up lupus nephritis
CN114934021B (zh) * 2022-04-21 2023-08-08 复旦大学附属儿科医院 一种Angptl3敲除的鼠永生化足细胞系及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005825A2 (en) * 1999-07-16 2001-01-25 Hyseq, Inc. Nucleic acid sequences encoding putative angiopoietin proteins
JP2005080508A (ja) * 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
CN1980686A (zh) * 2004-04-05 2007-06-13 安斯泰来制药有限公司 抗肥胖药
MX2007000783A (es) * 2004-07-20 2007-04-09 Genentech Inc Inhibidores de proteina angiopoietina tipo 4, combinaciones y su uso.
EP2007899B1 (en) * 2006-03-20 2017-06-07 Celldex Therapeutics, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
CA2903133C (en) * 2007-05-31 2021-10-19 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health N-acetyl mannosamine or derivatives thereof for use in treating a kidney disorder in a mammal

Also Published As

Publication number Publication date
JP5904560B2 (ja) 2016-04-13
CA2801579C (en) 2021-12-14
JP2013528625A (ja) 2013-07-11
PL2575858T3 (pl) 2018-08-31
CN103140234B (zh) 2016-12-21
CA2801579A1 (en) 2011-12-08
HK1252916A1 (en) 2019-06-06
AU2011261196A1 (en) 2013-01-10
WO2011153525A2 (en) 2011-12-08
KR20130132375A (ko) 2013-12-04
EP3318269B1 (en) 2024-03-13
NO2575858T3 (enExample) 2018-05-19
EP2575858A4 (en) 2014-01-01
EP2575858A2 (en) 2013-04-10
CN103140234A (zh) 2013-06-05
AU2011261196B2 (en) 2015-05-21
EP3318269A1 (en) 2018-05-09
WO2011153525A9 (en) 2012-04-19
DK2575858T3 (en) 2018-03-12
EP3318269C0 (en) 2024-03-13
PT2575858T (pt) 2018-03-22
CN107412729A (zh) 2017-12-01
EP2575858B1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
CL2012003643A1 (es) Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
BR112015001712A2 (pt) uso de s-pindolol para o tratamento da caquexia e sarcopenia
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
MX349796B (es) Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10.
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MX2015003140A (es) Formulaciones de enzalutamida.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
DK3888641T3 (da) Anvendelse af cannabidiol i behandling af anfald i forbindelse med doose-syndrom
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
CL2011001299A1 (es) Compuestos derivados de benzotiazoles; composicion farmaceutica; y su uso como inhibidores de raf para el tratamiento o profilaxis del cancer.
CL2012002250A1 (es) Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer.
EP3611184C0 (en) CELL PENETRATING PEPTIDE, CONJUGATE COMPRISING SAME, AND COMPOSITION COMPRISING THE CONJUGATE
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
CL2015002897A1 (es) Inhibidores de bace1
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
ES2711427T8 (es) Lactobacillus reuteri ATCC PTA 6475 para su uso en la prevención o el tratamiento de la pérdida ósea en mamíferos
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
MX383944B (es) Composiciones para el cuidado personal.
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico